Innovation, one of the main strategic drivers for Aché business, is demonstrated one of the main drivers of the business and is demonstrated in products, services and processes, boosting our growth and contributing to the Company’s continuity.
In addition to being vital for sustainability, innovation plays an important socialand environmental role in promoting the discovery of drugs for unmet needs, preventing diseases, improving people’s quality of life, contributing to longevity, offering effective treatments with greater adherence and convenience, minimizing hospital costs and reducing impacts on natural resources.
Keeping its eyes focused on the future, in 2021 the Company reinforced its role in the development of molecules that had their term of patent protection reduced due to the decision of unconstitutionality of the sole paragraph of Article 40 of the Intellectual Property Code, aiming to be the first laboratory to make similar drugs available to the Brazilian population.
In addition, Aché’s DNA constantly aims at new differentiated therapeutic solutions, thus fulfilling its purpose of bringing more life to people.
In order to maintain our pioneering spirit and offer the market increasingly innovative solutions and products, we invested BRL 153 million in innovation, 47% more than in the previous year we launched 35 products and ended the year with a pipeline with 193 projects, among similar products, incremental and radical innovation.
In 2021, once again, Aché stood out, winning the 1st place in the Innovation Value Award, in the Life Sciences category, appearing as the most innovative national pharmaceutical industry. This recognition confirms the assertiveness of strategies in incremental and radical innovation, implemented over the years.
Introduction of worldwide existing assets in Brazil or promotion of incremental improvements.+
Efficient therapeutic responses in high- complexity diseases when compared to synthetic manufacture originals.+